Ponatinib for Philadelphia chromosome-positive ALL in real-world settings
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well ponatinib works for adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL) when used as a first treatment, either alone or with other therapies. It aims to help doctors understand the real-world benefits and outcomes of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- You must have received ponatinib as your first treatment, either by itself or along with chemotherapy or immunotherapy.
- Your ponatinib treatment must have been given under Italy's Law 648/96 (a special access program).
- You either have medical records from at least 18 months after starting ponatinib, or you have passed away or been lost to follow-up at any point after starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests a new combination of four drugs (LP-118, ponatinib, dexamethasone, and blinatumomab) to treat a specific type of blood cancer called Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL). The study aims to see if this combination is safe and effective in newly diagnosed adults.
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.